India's Biocon Issues One-For-One Bonus Shares, Says Acquisitions, New Drug Development To Drive Earnings
This article was originally published in PharmAsia News
Executive Summary
BANGALORE, India - India's largest biotechnology drug firm Biocon said clinical trials for diabetes, psorasis, arthritis and cancer drugs are progressing and it plans to launch a new cardio-diabetes division to focus on brand building for its statin Statix (atorvastatin)